Notably, mogamulizumab/Poteligeo, an anti-CCR4 targeted therapy for refractory adult T cell leukemia and mycosis fungoides has received FDA approval (146). This evidence concerns the gene CCR4 and adult T-cell leukemia/lymphoma.